The utility of HCV core antigen for evaluation of viremia at 48 weeks posttreatment with direct-acting antivirals

被引:0
作者
Ko, Ping-Hung [1 ,2 ]
Tseng, Chih-Wei [1 ,2 ]
Tseng, Kuo-Chih [1 ,2 ]
Chen, Yen-Chun [1 ,2 ]
Hsu, Ching-Sheng [1 ,2 ,3 ]
机构
[1] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Internal Med, Div Gastroenterol, 2 Minsheng Rd, Chiayi 622401, Taiwan
[2] Tzuchi Univ, Sch Med, Hualien, Taiwan
[3] Tzu Chi Univ, Sch Postbaccalaureate Chinese Med, Hualien, Taiwan
关键词
direct-acting antivirals; hepatitis C; hepatitis C core antigen; HEPATITIS-C VIRUS; SUSTAINED VIROLOGICAL RESPONSE; NATURAL-HISTORY; MANAGEMENT;
D O I
10.1002/aid2.13316
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The hepatitis C virus core antigen (HCV-cAg) assay is a cheap and rapid alternative to HCV-RNA detection, while the results were limited to 12 weeks following direct-acting antiviral (DAA) treatment. In this study we aimed to investigate the role of the HCV-cAg assay up to 48 weeks after DAA treatment. We enrolled 98 patients with chronic HCV infection who received DAA treatment in this study. Plasma samples were assessed for HCV-RNA (AmpliPrep/COBAS TaqMan assay, Roche) and HCV-cAg (Abbott ARCHITECT HCV-cAg assay) levels at baseline, 12 weeks (P12) and 48 weeks (P48) after DAA treatment. The sensitivity and specificity of HCV-cAg were compared with those of HCV-RNA. A total of 284 samples from 98 enrolled participants were analyzed. HCV-cAg levels changed in parallel with HCV-RNA levels in HCV-infected patients during and after DAA therapy. HCV-cAg levels showed excellent correlation with HCV viral load (R = 0.951, R-2 = 0.905, beta = 0.951, and P < .001). The overall sensitivity and specificity for HCV-cAg in detecting quantifiable HCV-RNA thresholds were 96.9% and 100%, respectively. Three patients with baseline HCV viremia had nonreactive HCV-cAg (false-negative rate was 1.02%); none of the patients were HCV-cAg positive and HCV-RNA negative. At 48 weeks after DAA treatment, the HCV-cAg assay detected all patients with viremia, demonstrating 100% sensitivity and specificity. In conclusions, the HCV-cAg assay has high sensitivity and specificity for the detection of pre- and post-DAA treatment viremia and may be a useful tool to confirm viremia at P12 and P48.
引用
收藏
页码:80 / 86
页数:7
相关论文
共 32 条
  • [1] Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection
    Aghemo, Alessio
    Degasperi, Elisabetta
    De Nicola, Stella
    Bono, Patrizia
    Orlandi, Anna
    D'Ambrosio, Roberta
    Soffredini, Roberta
    Perbellini, Riccardo
    Lunghi, Giovanna
    Colombo, Massimo
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (09) : 1331 - 1336
  • [2] Hepatitis C core antigen highly correlated to HCV RNA
    Chang, Christine
    Hung, Chao-Hung
    Wang, Jing-Houng
    Lu, Sheng-Nan
    [J]. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2018, 34 (12) : 684 - 688
  • [3] Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
    Chung, Raymond T.
    Ghany, Marc G.
    Kim, Arthur Y.
    Marks, Kristen M.
    Naggie, Susanna
    Vargas, Hugo E.
    Aronsohn, Andrew I.
    Bhattacharya, Debika
    Broder, Tina
    Falade-Nwulia, O.
    Fontana, Robert J.
    Gordon, Stuart C.
    Heller, Theo
    Holmberg, Scott D.
    Jhaveri, Ravi
    Jonas, Maureen M.
    Kiser, Jennifer J.
    Linas, Benjamin P.
    Lo Re, Vincent, III
    Morgan, Timothy R.
    Nahass, Ronald G.
    Peters, Marion G.
    Reddy, K. Rajender
    Reynolds, Andrew
    Scott, John D.
    Searson, Gloria
    Swan, Tracy
    Terrault, Norah A.
    Trooskin, Stacey B.
    Wong, John B.
    Workowski, Kimberly A.
    [J]. CLINICAL INFECTIOUS DISEASES, 2018, 67 (10) : 1477 - 1492
  • [4] Hepatitis C virus proteins
    Dubuisson, Jean
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (17) : 2406 - 2415
  • [5] EASL Recommendations on Treatment of Hepatitis C 2018
    Pawlotsky J.-M.
    Negro F.
    Aghemo A.
    Berenguer M.
    Dalgard O.
    Dusheiko G.
    Marra F.
    Puoti M.
    Wedemeyer H.
    [J]. JOURNAL OF HEPATOLOGY, 2018, 69 (02) : 461 - 511
  • [6] Fan ZJ, 2019, MEDICINE, V98, DOI [10.1097/MD.0000000000014795, 10.1097/md.0000000000014795]
  • [7] Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection A Systematic Review and Meta-analysis
    Freiman, J. Morgan
    Tran, Trang M.
    Schumacher, Samuel G.
    White, Laura F.
    Ongarello, Stefano
    Cohn, Jennifer
    Easterbrook, Philippa J.
    Linas, Benjamin P.
    Denkinger, Claudia M.
    [J]. ANNALS OF INTERNAL MEDICINE, 2016, 165 (05) : 345 - +
  • [8] Epidemiology and natural history of HCV infection
    Hajarizadeh, Behzad
    Grebely, Jason
    Dore, Gregory J.
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2013, 10 (09) : 553 - 562
  • [9] The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation
    Hamaguchi, Masahide
    Kojima, Takao
    Itoh, Yoshito
    Harano, Yuichi
    Fujii, Kota
    Nakajima, Tomoaki
    Kato, Takahiro
    Takeda, Noriyuki
    Okuda, Junichi
    Ida, Kazunori
    Kawahito, Yutaka
    Yoshikawa, Toshikazu
    Okanoue, Takeshi
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (12) : 2708 - 2715
  • [10] Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1386-patient study from Taiwan
    Huang, J. -F.
    Yu, M. -L.
    Lee, C. -M.
    Dai, C. -Y.
    Hou, N. -J.
    Hsieh, M. -Y.
    Wang, J. -H.
    Lu, S. -N.
    Sheen, I. -S.
    Lin, S. -M.
    Chuang, W. -L.
    Liaw, Y. -F.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (09) : 1029 - 1037